Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy

References

• BrayF, FerlayJ, SoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Jedy-AgbaE, CuradoMP, OgunbiyiO, et al. Cancer incidence in Nigeria: a report from population-based cancer registries. Cancer Epidemiol. 2012;36:e271–e278. doi:10.1016/j.canep.2012.04.00722621842
   PubMed Web of Science ®Google Scholar
• LimE, Metzger-FilhoO, WinerEP. The natural history of hormone receptor-positive breast cancer. Oncology. 2012;26:688–694, 696.22957400
   PubMed Web of Science ®Google Scholar
• AwofesoO, RobertsAA, SalakoO, et al. Prevalence and Pattern of Late-Stage Presentation in Women with Breast and Cervical Cancers in Lagos University Teaching Hospital, Nigeria. Niger Med J. 2018;59:74–79. doi:10.4103/nmj.NMJ_112_1731423046
   PubMedGoogle Scholar
• AdesunkanmiAR, LawalOO, AdelusolaKA, et al. The severity, outcome and challenges of breast cancer in Nigeria. Breast. 2006;15:399–409. doi:10.1016/j.breast.2005.06.00816085418
   PubMed Web of Science ®Google Scholar
• Jedy-AgbaE, McCormackV, OlaomiO, et al. Determinants of stage at diagnosis of breast cancer in Nigerian women: sociodemographic, breast cancer awareness, health care access and clinical factors. Cancer Causes Control. 2017;28(7):685–697. doi:10.1007/s10552-017-0894-y28447308
   PubMed Web of Science ®Google Scholar
• NwaforCC, KeshinroSO. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: private practice experience. Niger J Clin Pract. 2015;18(4):553–558. doi:10.4103/1119-3077.15690525966732
   PubMed Web of Science ®Google Scholar
• AdebamowoCA, FamootoA, OgundiranTO, et al. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008;110(1):183–188. doi:10.1007/s10549-007-9694-517674190
   PubMed Web of Science ®Google Scholar
• EggemannH, AltmannU, CostaSD, et al. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J Cancer Res Clin Oncol. 2018;144(2):337–341. doi:10.1007/s00432-017-2539-729098396
   PubMed Web of Science ®Google Scholar
• SauterER. Breast Cancer Prevention: current Approaches and Future Directions. Eur J Breast Health. 2018;14:64–71. doi:10.5152/ejbh.2018.397829774312
   PubMed Web of Science ®Google Scholar
• LeeWL, ChengMH, ChaoHT, et al. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwan J Obstet Gynecol. 2008;47(1):24–31. doi:10.1016/S1028-4559(08)60051-018400579
   PubMed Web of Science ®Google Scholar
• DaviesC, PanH, GodwinJ, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816. doi:10.1016/S0140-6736(12)61963-123219286
   PubMed Web of Science ®Google Scholar
• Group EBCTC. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–1467. doi:10.1016/S0140-6736(97)11423-49605801
   PubMed Web of Science ®Google Scholar
• PanH, GrayR, BraybrookeJ, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377:1836–1846. doi:10.1056/NEJMoa170183029117498
   PubMed Web of Science ®Google Scholar
• HernandezRK, SorensenHT, PedersenL, et al. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009;115(19):4442–4449. doi:10.1002/cncr.2450819569248
   PubMed Web of Science ®Google Scholar
• FisherB, CostantinoJP, RedmondCK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–537. doi:10.1093/jnci/86.7.5278133536
   PubMed Web of Science ®Google Scholar
• CuzickJ, SestakI, BonanniB, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827–1834. doi:10.1016/S0140-6736(13)60140-323639488
   PubMed Web of Science ®Google Scholar
• CookeAL, MetgeC, LixL, et al. Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol. 2008;26(32):5227–5232. doi:10.1200/JCO.2007.15.712318838712
   PubMed Web of Science ®Google Scholar
• TzengHE, MuoCH, ChenHT, et al. Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study. BMC Musculoskelet Disord. 2015;16(1):123. doi:10.1186/s12891-015-0580-825989902
   PubMed Web of Science ®Google Scholar
• PowlesTJ, HickishT, KanisJA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14(1):78–84. doi:10.1200/JCO.1996.14.1.788558225
   PubMed Web of Science ®Google Scholar
• DestaZ, WardBA, SoukhovaNV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310(3):1062–1075. doi:10.1124/jpet.104.06560715159443
   PubMed Web of Science ®Google Scholar
• BertilssonL, DahlML, DalenP, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53(2):111–122. doi:10.1046/j.0306-5251.2001.01548.x11851634
   PubMed Web of Science ®Google Scholar
• GoetzMP, KamalA, AmesMM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther. 2008;83(1):160–166. doi:10.1038/sj.clpt.610036717882159
   PubMed Web of Science ®Google Scholar
• KingMC, WieandS, HaleK, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251–2256. doi:10.1001/jama.286.18.225111710890
   PubMed Web of Science ®Google Scholar
• KruscheCA, WulfingP, KerstingC, et al. Histone deacetylase-1 and −3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005;90(1):15–23. doi:10.1007/s10549-004-1668-215770522
   PubMed Web of Science ®Google Scholar
• MullerBM, JanaL, KasajimaA, et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer–overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer. 2013;13:215. doi:10.1186/1471-2407-13-21523627572
   PubMed Web of Science ®Google Scholar
• OieS, MatsuzakiK, YokoyamaW, et al. HDAC3 regulates stability of estrogen receptor alpha mRNA. Biochem Biophys Res Commun. 2013;432(2):236–241. doi:10.1016/j.bbrc.2013.02.00723402757
   PubMed Web of Science ®Google Scholar
• KimSS, LeeMH, LeeMO. Histone methyltransferases regulate the transcriptional expression of ERalpha and the proliferation of tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 2020;180(1):45–54. doi:10.1007/s10549-019-05517-031897900
   PubMed Web of Science ®Google Scholar
• FanningSW, MayneCG, DharmarajanV, et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 2016;5. doi:10.7554/eLife.12792
   Google Scholar
• YeL, LinC, WangX, et al. Epigenetic silencing of SALL 2 confers tamoxifen resistance in breast cancer. EMBO Mol Med. 2019;11(12):e10638. doi:10.15252/emmm.20191063831657150
   PubMed Web of Science ®Google Scholar
• LimYC, DestaZ, FlockhartDA, et al. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55:471–478. doi:10.1007/s00280-004-0926-715685451
   PubMed Web of Science ®Google Scholar
• EbeshiBU, BolajiOO, Masimirembwa CM. CytochromeP450 2D6 (CYP2D6) Genotype and Phenotype Determination in the Nigerian Populations. Asian J Pharm Hea Sci. 2011;1:47–54.
   Google Scholar
• ConsortiumCPIGuideline for CYP2D6 and Tamoxifen Therapyhttps://cpicpgx.org/. Accessed 916, 2020.
   Google Scholar
• KuchenbaeckerKB, HopperJL, BarnesDR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–2416. doi:10.1001/jama.2017.711228632866
   PubMed Web of Science ®Google Scholar
• ZhengY, WalshT, GulsunerS, et al. Inherited Breast Cancer in Nigerian Women. J Clin Oncol. 2018;36:2820–2825. doi:10.1200/JCO.2018.78.397730130155
   PubMed Web of Science ®Google Scholar
• RedingKW, BernsteinJL, LangholzBM, et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat. 2010;123:491–498. doi:10.1007/s10549-010-0769-320135344
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-015894097
   PubMed Web of Science ®Google Scholar
• AdejumoAA, AjamuOJ, AkanbiOO, et al. Epidemiology and Challenges of Managing Breast Cancer in Keffi, North-Central Nigeria: A Preliminary Report. Niger Med J. 2019;60(4):193–197. doi:10.4103/nmj.NMJ_45_1931831939
   PubMedGoogle Scholar
• LegareS, BasikM. Minireview: the Link Between ERalpha Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer. Mol Endocrinol. 2016;30(9):965–976. doi:10.1210/me.2016-107227581354
   PubMedGoogle Scholar
• SharmaD, BlumJ, YangX, et al. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol. 2005;19(7):1740–1751. doi:10.1210/me.2004-001115746193
   PubMedGoogle Scholar
• ZhouQ, AtadjaP, DavidsonNE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther. 2007;6:64–69. doi:10.4161/cbt.6.1.354917172825
   PubMed Web of Science ®Google Scholar
• IzadiP, NoruziniaM, KarimipoorM, et al. Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer. Cell J. 2012;14:102–109.23508069
   PubMed Web of Science ®Google Scholar
• SproulD, MeehanRR. Genomic insights into cancer-associated aberrant CpG island hypermethylation. Brief Funct Genomics. 2013;12(3):174–190. doi:10.1093/bfgp/els06323341493
   PubMed Web of Science ®Google Scholar
• de Souza Rocha SimoniniP, BreilingA, GuptaN, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 2010;70(22):9175–9184. doi:10.1158/0008-5472.CAN-10-131820978187
   PubMed Web of Science ®Google Scholar
• KullmannK, DeryalM, OngMF, et al. DNMT1 genetic polymorphisms affect breast cancer risk in the central European Caucasian population. Clin Epigenetics. 2013;5(1):7. doi:10.1186/1868-7083-5-723638630
   PubMed Web of Science ®Google Scholar
• XiangG, ZhenkunF, ShuangC, et al. Association of DNMT1 gene polymorphisms in exons with sporadic infiltrating ductal breast carcinoma among Chinese Han women in the Heilongjiang Province. Clin Breast Cancer. 2010;10(5):373–377. doi:10.3816/CBC.2010.n.04920920981
   PubMed Web of Science ®Google Scholar
• The International Genome Sample Resource. Human Genome Project. Available from: https://www.internationalgenome.org/. Accessed September 25, 2020.
   Google Scholar
• HalsallJA, TurnerBM. Histone deacetylase inhibitors for cancer therapy: an evolutionarily ancient resistance response may explain their limited success. Bioessays. 2016;38:1102–1110. doi:10.1002/bies.20160007027717012
   PubMed Web of Science ®Google Scholar
• ConnollyRM, RudekMA, PiekarzR. Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol. 2017;13(13):1137–1148. doi:10.2217/fon-2016-052628326839
   PubMed Web of Science ®Google Scholar
• YangZ, ZhouL, WuLM, et al. Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy. Clin Chem Lab Med. 2010;48(12):1785–1791. doi:10.1515/CCLM.2010.35320731616
   PubMed Web of Science ®Google Scholar
• StrattonMR, CampbellPJ, FutrealPA. The cancer genome. Nature. 2009;458:719–724. doi:10.1038/nature0794319360079
   PubMed Web of Science ®Google Scholar
• FumagalliD, WilsonTR, SalgadoR, et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Ann Oncol. 2016;27(10):1860–1866. doi:10.1093/annonc/mdw28627672107
   PubMed Web of Science ®Google Scholar
• WangP, BahreiniA, GyanchandaniR, et al. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clin Cancer Res. 2016;22(5):1130–1137. doi:10.1158/1078-0432.CCR-15-153426500237
   PubMed Web of Science ®Google Scholar
• TakeshitaT, YamamotoY, Yamamoto-IbusukiM, et al. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res. 2015;166:540–553 e542. doi:10.1016/j.trsl.2015.09.00326434753
   PubMed Web of Science ®Google Scholar
• GriffithOL, SpiesNC, AnuragM, et al. The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018;9(1):3476. doi:10.1038/s41467-018-05914-x30181556
   PubMed Web of Science ®Google Scholar
• PittJJ, ZhengY, OlopadeOI. Genetic Ancestry May Influence the Evolutionary Trajectory of Cancers. Cancer Cell. 2018;34:529–530. doi:10.1016/j.ccell.2018.09.00630300575
   PubMed Web of Science ®Google Scholar
• YuanJ, HuZ, MahalBA, et al. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell. 2018;34:549–560 e549. doi:10.1016/j.ccell.2018.08.01930300578
   PubMed Web of Science ®Google Scholar
• BenevolenskayaEV, IslamAB, AhsanH, et al. DNA methylation and hormone receptor status in breast cancer. Clin Epigenetics. 2016;8(1):17. doi:10.1186/s13148-016-0184-726884818
   PubMed Web of Science ®Google Scholar
• Genomes ProjectC, AutonA, BrooksLD, et al. A global reference for human genetic variation. Nature. 2015;526:68–74. doi:10.1038/nature1539326432245
   PubMed Web of Science ®Google Scholar
• RajendranBK, DengCX. Characterization of potential driver mutations involved in human breast cancer by computational approaches. Oncotarget. 2017;8:50252–50272. doi:10.18632/oncotarget.1722528477017
   PubMedGoogle Scholar
• WeaverKE, CamachoF, HwangW, et al. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol. 2013;36(2):181–187. doi:10.1097/COC.0b013e3182436ec122314001
   PubMed Web of Science ®Google Scholar
• JohnstonSR, HaynesBP, SmithIE, et al. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet. 1993;342(8886–8887):1521–1522. doi:10.1016/S0140-6736(05)80088-17902904
   PubMed Web of Science ®Google Scholar
• OguntolaAS, AdeotiML, AkanbiOO. Non-adherence to the Use of Tamoxifen in the First year by the Breast Cancer Patients in an African Population. East Central African J Surg. 2011;16:52–56.
   Google Scholar
• DecensiA, GandiniS, SerranoD, et al. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol. 2007;25(27):4201–4209. doi:10.1200/JCO.2006.09.431817709798
   PubMed Web of Science ®Google Scholar
• Guerrieri-GonzagaA, BotteriE, LazzeroniM, et al. Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. Ann Oncol. 2010;21(5):949–954. doi:10.1093/annonc/mdp40819858087
   PubMed Web of Science ®Google Scholar
• DeCensiA, PuntoniM, Guerrieri-GonzagaA, et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. J Clin Oncol. 2019;37(19):1629–1637. doi:10.1200/JCO.18.0177930973790
   PubMed Web of Science ®Google Scholar
• SinghDD, DharanipragadaK, DS, et al. Oral versus topical tamoxifen in cyclical mastalgia-A randomized controlled trial. Breast J. 2020;26(4):743–747. doi:10.1111/tbj.1367431713297
   PubMed Web of Science ®Google Scholar
• VogelVG, CostantinoJP, WickerhamDL, et al. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295(23):2727–2741. doi:10.1001/jama.295.23.joc6007416754727
   PubMed Web of Science ®Google Scholar
• PinskyPF, MillerEA, Heckman-StoddardBM, et al. Breast Cancer Characteristics and Survival among Users versus Nonusers of Raloxifene. Cancer Prev Res. 2020;13(1):83–90. doi:10.1158/1940-6207.CAPR-19-0393
   Web of Science ®Google Scholar